Core Laboratories Inc.
CLB
$11.18
$0.211.91%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.67% | 0.80% | 7.22% | 2.11% | 1.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.67% | 0.80% | 7.22% | 2.11% | 1.00% |
| Cost of Revenue | -4.89% | 4.61% | 10.54% | 2.63% | 3.01% |
| Gross Profit | -3.72% | -13.69% | -3.95% | 0.22% | -6.63% |
| SG&A Expenses | 16.24% | 6.04% | -8.64% | 81.94% | -28.15% |
| Depreciation & Amortization | -3.28% | -5.42% | -6.44% | -4.24% | -4.97% |
| Other Operating Expenses | -286.70% | 40.43% | -850.00% | -450.93% | 64.32% |
| Total Operating Expenses | -3.31% | 4.52% | 7.53% | 5.69% | -1.06% |
| Operating Income | -21.12% | -27.49% | 5.12% | -19.30% | 34.87% |
| Income Before Tax | -64.74% | 5.31% | 44.86% | -18.32% | 68.68% |
| Income Tax Expenses | 5.31% | -52.21% | 103.51% | 149.72% | 171.80% |
| Earnings from Continuing Operations | -98.02% | 206.86% | 30.20% | -59.92% | 42.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.41% | 71.91% | -800.00% | -90.36% | -291.30% |
| Net Income | -104.78% | 236.65% | 26.88% | -60.47% | 35.69% |
| EBIT | -21.12% | -27.49% | 5.12% | -19.30% | 34.87% |
| EBITDA | -16.13% | -22.94% | 2.81% | -16.64% | 20.73% |
| EPS Basic | -104.80% | 235.50% | 26.22% | -60.67% | 34.97% |
| Normalized Basic EPS | -23.77% | -30.38% | 5.99% | -28.89% | 41.24% |
| EPS Diluted | -104.80% | 289.45% | 31.58% | -60.42% | 37.40% |
| Normalized Diluted EPS | -22.37% | -30.38% | 6.05% | -28.94% | 41.26% |
| Average Basic Shares Outstanding | -0.18% | 0.45% | 0.49% | 0.50% | 0.48% |
| Average Diluted Shares Outstanding | -1.95% | 0.45% | 0.45% | 0.52% | 0.47% |
| Dividend Per Share | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | -21.95% | -0.70% | -0.21% | 1.54% | -0.26% |